In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range…
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday’s session after the company reported worse-than-expected first-quarter EPS results.…
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday’s regular session. The market value of…
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of…
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday’s session after the company priced a $1.7 million…
What 5 Analyst Ratings Have To Say About IGM Biosciences
In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range…
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results.
Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday.
Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.
RBC Capital’s Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its potential in lupus and rheumatoid arthritis.
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.